Phio Pharmaceuticals Ownership | Who Owns Phio Pharmaceuticals?
Phio Pharmaceuticals Ownership Summary
Phio Pharmaceuticals is owned by 5.57% institutional investors, 3.94% insiders, and 90.49% retail investors. Scientech research is the largest institutional shareholder, holding 0% of PHIO shares. Macquarie Healthcare I is the top mutual fund, with 0.87% of its assets in Phio Pharmaceuticals shares.
PHIO Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Phio Pharmaceuticals | 5.57% | 3.94% | 90.49% |
| Sector | Healthcare Stocks | 244.59% | 12.11% | -156.70% |
| Industry | Biotech Stocks | 379.61% | 11.70% | -291.31% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Scientech research | - | - | - |
| Nbc securities | - | - | - |
| Gsa capital partners llp | - | - | - |
| Two sigma securities | - | - | - |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Scientech research | - | - | - |
| Nbc securities | - | - | - |
| Gsa capital partners llp | - | - | - |
| Two sigma securities | - | - | - |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Nbc securities | - | - | -1.07K |
| Two sigma securities | - | - | -15.22K |
| Gsa capital partners llp | - | - | -19.86K |
| Scientech research | - | - | -30.03K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Scientech research | - | - | -30.03K |
| Gsa capital partners llp | - | - | -19.86K |
| Two sigma securities | - | - | -15.22K |
| Nbc securities | - | - | -1.07K |
Sold Out
| Holder | Change |
|---|---|
| Nbc securities | -1.07K |
| Two sigma securities | -15.22K |
| Gsa capital partners llp | -19.86K |
| Scientech research | -30.03K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 24 | - | 647,127 | -3.20% | 5 | 16.82% | 10 | -47.37% | 8 | - |
| Mar 31, 2026 | 24 | - | 668,490 | - | 5 | - | 24 | - | - | - |
| Jun 30, 2025 | 11 | - | 164,722 | - | 3 | - | 11 | - | - | - |
| Dec 31, 2022 | 11 | -15.38% | 575,219 | -20.85% | 4 | 14.91% | 3 | -57.14% | 7 | 75.00% |
| Sep 30, 2022 | 13 | 30.00% | 726,716 | -6.72% | 5 | 16.35% | 7 | 133.33% | 4 | -33.33% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Macquarie Healthcare I | 50.00K | 0.87% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 94.26K | 0.81% | - |
| Fidelity Extended Market Index | 61.47K | 0.53% | -19.13K |
| Nomura Healthcare Fund Class I | 50.00K | 0.43% | - |
| Spartan Extended Market Index Pool E | 7.45K | 0.18% | 7.41K |
| Spartan Extended Market Index Pool F | 17.59K | 0.15% | 116.00 |
| NT Ext Equity Mkt Idx Fd - L | 15.35K | 0.13% | - |
| Fidelity Series Total Market Index | 14.66K | 0.13% | - |
| Fidelity Total Market Index | 13.29K | 0.11% | - |
| Northern Trust Extended Eq Market Idx | 12.61K | 0.11% | -2.74K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Aug 19, 2026 | Plott Ronald Todd | - | Buy | $17.10K |
| Aug 18, 2026 | Bitterman Robert J | Chairman, Pres. & CEO | Buy | $10.60K |
| Jun 26, 2026 | Bitterman Robert J | Chairman, Pres. & CEO | Buy | $9.90K |
| Dec 31, 2025 | Bitterman Robert J | Chairman, Pres. & CEO | Buy | $5.15K |
| Dec 23, 2025 | Bitterman Robert J | Chairman, Pres. & CEO | Buy | $5.10K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | 2 | - |
| 2026 Q2 | 1 | - |
| 2026 Q1 | - | - |
| 2025 Q4 | 4 | - |
| 2025 Q3 | - | - |
PHIO Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools